OLMA Stock Analysis: Olema Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 720m USD | 12M Return: -24% | US68062P1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.7M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing therapies for womens cancers, with a particular emphasis on breast cancer. Its lead product candidate, palazestrant, is an estrogen receptor antagonist and selective ER degrader being evaluated in a pivotal Phase 3 trial (OPERA-01) for second/third-line ER+/HER2- metastatic breast cancer, both as monotherapy and in combination with CDK4/6 inhibitors and other targeted agents. The company is also advancing OP-3136, an oral small-molecule KAT6 inhibitor, in early-stage trials for breast and other solid tumors. As a clinical-stage biotech, Olema has not yet commercialized any products and relies on capital markets to fund its research and development pipeline.
- OPERA-01 Phase 3 palazestrant data is pivotal stock catalyst
- Competition intensifies from approved SERD therapies in breast cancer
- Cash burn raises dilution risk amid clinical development costs
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.34 > 3% & CFO -164.7m > Net Income -204.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.5m) vs 12m ago 22.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.10%; Δ -0.10% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.86 (Total Current Assets 469.9m - Total Current Liabilities 53.0m) / Total Assets 486.6m |
| B: -1.47 (Retained Earnings -713.8m / Total Assets 486.6m) |
| C: -0.47 (EBIT TTM -204.6m / Avg Total Assets 434.3m) |
| D: 7.69 (Book Value of Equity 430.6m / Total Liabilities 56.0m) |
| Altman-Z'' = 5.74 = AAA |
As of October 08, 2026, the stock is trading at USD 7.94 with a total of 818,546 shares traded. Over the past week, the price has changed by -8.10%, over one month by -27.72%, over three months by -37.13% and over the past year by -23.95%.
Current recommended Stop Loss: 7.30 (which is 8.1% or 1.3 ATR below the current price).
Olema Pharmaceuticals has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy OLMA.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 36.5 | 359.7% |
P/B = 1.7944
Revenue TTM = 0.0 USD
EBIT TTM = -204.6m USD
EBITDA TTM = -204.0m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 660k USD (from shortTermDebt, last quarter)
Debt = 4.32m USD (corrected: LT Debt 3.00m + ST Debt 660k) + Leases 660k
Net Debt = -456.8m USD (calculated: Debt 4.32m - CCE 461.1m)
Enterprise Value = 262.9m USD (719.7m + Debt 4.32m - CCE 461.1m)
Interest Coverage Ratio = unknown (Ebit TTM -204.6m / Interest Expense TTM 0.0)
EV/FCF = -1.60x (Enterprise Value 262.9m / FCF TTM -164.7m)
FCF Yield = -62.66% (FCF TTM -164.7m / Enterprise Value 262.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.54 (Enterprise Value 262.9m / Total Assets 486.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.32m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -161.6m (EBIT -204.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.86 (Total Current Assets 469.9m / Total Current Liabilities 53.0m)
Debt / Equity = 0.01 (Debt 4.32m / totalStockholderEquity, last quarter 430.6m)
Debt / EBITDA = 2.24 (negative EBITDA) (Net Debt -456.8m / EBITDA -204.0m)
Debt / FCF = 2.77 (negative FCF - burning cash) (Net Debt -456.8m / FCF TTM -164.7m)
Total Stockholder Equity = 424.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.10% (Net Income -204.6m / Total Assets 486.6m)
RoE = -48.22% (Net Income TTM -204.6m / Total Stockholder Equity 424.3m)
RoCE = -47.88% (EBIT -204.6m / Capital Employed (Equity 424.3m + L.T.Debt 3.00m))
RoIC = -37.22% (negative operating profit) (NOPAT -161.6m / Invested Capital 434.2m)
WACC = 5.35% (E(719.7m)/V(724.0m) * Re(5.38%) + D(4.32m)/V(724.0m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 5.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.47 | Cagr: 32.37%
[DCF] Fair Price = unknown (Cash Flow -164.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.32 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.63 | Chg30d=+1.72% | Revisions=-55% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.38 | Chg30d=+1.83% | Revisions=-55% | GrowthEPS=-27.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.64 | Chg30d=+1.90% | Revisions=-55% | GrowthEPS=-10.9% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -67% (up=3, down=21)